Urovant Sciences Ltd.
Healthcare · Pharmaceutical Preparations · D0 · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY20 | FY19 | FY18 | |
|---|---|---|---|
| Revenue | — | — | — |
| Operating income | — | — | — |
| Net income | −$146.7M | −$111.3M | −$37.1M |
| Total assets | $63.3M | $100.1M | $13.0M |
| Total liabilities | $121.3M | $25.4M | $5.9M |
| Equity | −$58.0M | $74.8M | $7.1M |
| EPS (diluted) | — | — | — |
| Shares out. | 30.8M | 30.3M | 20.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2020- Operating margin
- —
- Net margin
- —
- Return on equity
- 253.0%
- Return on assets
- −231.8%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 191.6%
- Debt / equity
- —
- Book value / share
- $-1.88
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2020- Accruals / assets
- −70.6%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 2 good- Negative shareholder equity
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Director / officer change · Amended charter or bylaws · Other material eventMar 29, 2021
- Shareholder vote · Other material eventMar 24, 2021
- Results of operationsFeb 12, 2021
- Regulation FD disclosureFeb 11, 2021
- Entered a material agreement · New financial obligationFeb 9, 2021
- Regulation FD disclosureDec 23, 2020
- Regulation FD disclosureNov 24, 2020
- Regulation FD disclosureNov 17, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12BApr 8, 2021
- EFFECTMar 31, 2021
- 4FORM 4 SUBMISSIONMar 31, 2021
- 4FORM 4 SUBMISSIONMar 31, 2021
- 4FORM 4 SUBMISSIONMar 31, 2021
- 4FORM 4 SUBMISSIONMar 31, 2021
- 4FORM 4 SUBMISSIONMar 31, 2021
- 4FORM 4 SUBMISSIONMar 31, 2021
- 4FORM 4 SUBMISSIONMar 31, 2021
- 4FORM 4 SUBMISSIONMar 31, 2021
- 4FORM 4 SUBMISSIONMar 31, 2021
- 4FORM 4 SUBMISSIONMar 31, 2021
- SC 13D/AMar 30, 2021
- SC 13E3/ASC 13E3 - AMENDMENT NO. 3Mar 29, 2021
- S-8 POSMar 29, 2021
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.